Cardiac dysfunction associated withtrastuzumab

Karen Lisa Smith, Chau Dang, Andrew D. Seidman

Research output: Contribution to journalReview articlepeer-review

Abstract

The HER2/neu gene is amplified in ∼ 25% of breast cancers, leading to HER2 protein overexpression and shortened overall survival and time to relapse. Trastuzumab is a humanised, monoclonal antibody against HER2, which improves survival for women with metastatic HER2-overexpressing breast cancer and reduces the risk of recurrence in women with early stage HER2-overexpressing breast cancer. Cardiac toxicity was an unexpected finding in the pivotal Phase III trial leading to the approval of trastuzumab, and prospective cardiac monitoring has, therefore, been incorporated into more recent clinical trials of trastuzumab. This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity.

Original languageEnglish (US)
Pages (from-to)619-629
Number of pages11
JournalExpert Opinion on Drug Safety
Volume5
Issue number5
DOIs
StatePublished - Sep 2006
Externally publishedYes

Keywords

  • Breast cancer
  • Cardiac toxicity
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cardiac dysfunction associated withtrastuzumab'. Together they form a unique fingerprint.

Cite this